Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.39)
# 301
Out of 4,873 analysts
125
Total ratings
41.82%
Success rate
33.01%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNOV MediciNova | Maintains: Buy | $6 → $5 | $1.34 | +272.13% | 2 | Jun 16, 2025 | |
| MGNX MacroGenics | Maintains: Neutral | $5 → $3 | $1.38 | +118.18% | 2 | May 20, 2025 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Buy | $422 → $460 | $286.94 | +60.31% | 12 | May 2, 2025 | |
| HROW Harrow | Maintains: Buy | $69 → $65 | $31.58 | +105.83% | 2 | Apr 1, 2025 | |
| VXRT Vaxart | Maintains: Buy | $2.5 → $2 | $0.57 | +251.62% | 6 | Mar 27, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $11 → $20 | $5.68 | +252.11% | 3 | Mar 19, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $4 → $3 | $1.08 | +177.78% | 2 | Mar 14, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Buy | $38 → $35 | $14.32 | +144.41% | 2 | Mar 5, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $51 → $38 | $15.88 | +139.29% | 7 | Feb 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $109 → $96 | $26.52 | +261.99% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $23.27 | +157.84% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $0.30 | +398.01% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $26 | $6.63 | +292.45% | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $13.98 | +136.05% | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $7.16 | +179.33% | 9 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $37.29 | -8.82% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $122 → $92 | $34.00 | +170.59% | 3 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $5.43 | +2,478.27% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $2.39 | +3,665.69% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $5.10 | +3,037.25% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.74 | +187.36% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $1.92 | +2,197.65% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $1.79 | +4,927.93% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $6.47 | +8.19% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.09 | +412,744.04% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $270 | $1.06 | +25,371.70% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $13.55 | +468.48% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.79 | +80,346.93% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.44 | +63.71% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $105.41 | -63.00% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $3.83 | +787.73% | 1 | Mar 13, 2020 |
MediciNova
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.34
Upside: +272.13%
MacroGenics
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.38
Upside: +118.18%
Madrigal Pharmaceuticals
May 2, 2025
Reiterates: Buy
Price Target: $422 → $460
Current: $286.94
Upside: +60.31%
Harrow
Apr 1, 2025
Maintains: Buy
Price Target: $69 → $65
Current: $31.58
Upside: +105.83%
Vaxart
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.57
Upside: +251.62%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $5.68
Upside: +252.11%
Lineage Cell Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.08
Upside: +177.78%
Denali Therapeutics
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $14.32
Upside: +144.41%
Arrowhead Pharmaceuticals
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $15.88
Upside: +139.29%
Viking Therapeutics
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $26.52
Upside: +261.99%
Jan 8, 2025
Initiates: Buy
Price Target: $60
Current: $23.27
Upside: +157.84%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $0.30
Upside: +398.01%
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $6.63
Upside: +292.45%
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $13.98
Upside: +136.05%
Aug 12, 2024
Reiterates: Buy
Price Target: $20
Current: $7.16
Upside: +179.33%
Aug 7, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $37.29
Upside: -8.82%
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $34.00
Upside: +170.59%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $5.43
Upside: +2,478.27%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $2.39
Upside: +3,665.69%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $5.10
Upside: +3,037.25%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.74
Upside: +187.36%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $1.92
Upside: +2,197.65%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $1.79
Upside: +4,927.93%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $6.47
Upside: +8.19%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.09
Upside: +412,744.04%
Nov 30, 2021
Maintains: Buy
Price Target: $500 → $270
Current: $1.06
Upside: +25,371.70%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $13.55
Upside: +468.48%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.79
Upside: +80,346.93%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $2.44
Upside: +63.71%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $105.41
Upside: -63.00%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $3.83
Upside: +787.73%